User login
Thrombolytic therapy decreased all-cause mortality in patients with hemodynamically stable pulmonary embolism associated with right ventricular dysfunction – those at "intermediate risk," according to a meta-analysis published online June 17 in JAMA.
The investigators described their study of 16 randomized, controlled clinical trials involving 2,115 patients as "the first analysis of thrombolysis in PE that has sufficient statistical power to detect associations with a meaningful mortality reduction." If their findings are confirmed in future randomized clinical trials, "there may be a shift in the treatment of selected patients with intermediate-risk PE using thrombolytics."
However, "the optimism regarding this clinical advantage must be tempered by [our] finding of significantly increased risk of major bleeding and intracranial hemorrhage associated with thrombolytic therapy, particularly for patients older than 65 years," said Dr. Saurav Chatterjee of the division of cardiology, St. Luke’s-Roosevelt Hospital Center of the Mount Sinai Health System, New York, and his associates (JAMA 2014;311:2414-21).
The study population included 1,499 patients who had hemodynamically stable PE associated with right ventricular dysfunction, the largest subset of patients seen in clinical practice and the group for whom the risks and benefits of thrombolysis are the most unclear.
After a mean follow-up of 82 days, overall mortality was 2.17% in patients who received thrombolysis, compared with 3.89% in those who received anticoagulation. In addition, the risk of recurrent PE was significantly lower with thrombolytic therapy (1.17%) than with anticoagulation (3.04%).
However, the rate of major bleeding was 9.24% for thrombolytic therapy, compared with 3.42% for anticoagulation. And the rate of intracranial hemorrhage was 1.46% for thrombolysis, compared with 0.19% for anticoagulation, the investigators said.
The bleeding risk was especially high in patients aged 65 years and older. Attenuation of this risk in younger patients suggests that they may be considered stronger candidates for thrombolytic therapy, Dr. Chatterjee and his associates said.
Dr. Chatterjee reported no financial conflicts; his associates reported ties to AstraZeneca, Boston Scientific, Cardiostem, Cordis, EKOS Corporation, Embolitech, GenWay, Johnson & Johnson, Soteria, and Vascular Magnetics.
 |
|
Dr. Chatterjee and his associates calculated the net clinical benefit of thrombolysis, and their result "suggests evidence of modest efficacy in intermediate-risk PE," said Dr. Joshua A. Beckman.
But their findings do not yet add up to a change in the standard of care. Each clinician must decide on an individualized basis which of these patients should receive thrombolytic therapy, based on clinical presentation, comorbid conditions, and both the physician’s and the patient’s tolerance of risk.
Dr. Beckman is in the cardiovascular division at Brigham and Women’s Hospital, Boston. He reported being a board member for Vascular Interventional Advances; receiving grant funding from Bristol-Myers Squibb; and consulting for AstraZeneca, Boston Scientific, Ferring, Merck, and Novartis. These remarks were taken from his editorial accompanying Dr. Chatterjee’s report (JAMA 2014;311:2385-6).
|
|
Dr. Chatterjee and his associates calculated the net clinical benefit of thrombolysis, and their result "suggests evidence of modest efficacy in intermediate-risk PE," said Dr. Joshua A. Beckman.
But their findings do not yet add up to a change in the standard of care. Each clinician must decide on an individualized basis which of these patients should receive thrombolytic therapy, based on clinical presentation, comorbid conditions, and both the physician’s and the patient’s tolerance of risk.
Dr. Beckman is in the cardiovascular division at Brigham and Women’s Hospital, Boston. He reported being a board member for Vascular Interventional Advances; receiving grant funding from Bristol-Myers Squibb; and consulting for AstraZeneca, Boston Scientific, Ferring, Merck, and Novartis. These remarks were taken from his editorial accompanying Dr. Chatterjee’s report (JAMA 2014;311:2385-6).
|
|
Dr. Chatterjee and his associates calculated the net clinical benefit of thrombolysis, and their result "suggests evidence of modest efficacy in intermediate-risk PE," said Dr. Joshua A. Beckman.
But their findings do not yet add up to a change in the standard of care. Each clinician must decide on an individualized basis which of these patients should receive thrombolytic therapy, based on clinical presentation, comorbid conditions, and both the physician’s and the patient’s tolerance of risk.
Dr. Beckman is in the cardiovascular division at Brigham and Women’s Hospital, Boston. He reported being a board member for Vascular Interventional Advances; receiving grant funding from Bristol-Myers Squibb; and consulting for AstraZeneca, Boston Scientific, Ferring, Merck, and Novartis. These remarks were taken from his editorial accompanying Dr. Chatterjee’s report (JAMA 2014;311:2385-6).
Thrombolytic therapy decreased all-cause mortality in patients with hemodynamically stable pulmonary embolism associated with right ventricular dysfunction – those at "intermediate risk," according to a meta-analysis published online June 17 in JAMA.
The investigators described their study of 16 randomized, controlled clinical trials involving 2,115 patients as "the first analysis of thrombolysis in PE that has sufficient statistical power to detect associations with a meaningful mortality reduction." If their findings are confirmed in future randomized clinical trials, "there may be a shift in the treatment of selected patients with intermediate-risk PE using thrombolytics."
However, "the optimism regarding this clinical advantage must be tempered by [our] finding of significantly increased risk of major bleeding and intracranial hemorrhage associated with thrombolytic therapy, particularly for patients older than 65 years," said Dr. Saurav Chatterjee of the division of cardiology, St. Luke’s-Roosevelt Hospital Center of the Mount Sinai Health System, New York, and his associates (JAMA 2014;311:2414-21).
The study population included 1,499 patients who had hemodynamically stable PE associated with right ventricular dysfunction, the largest subset of patients seen in clinical practice and the group for whom the risks and benefits of thrombolysis are the most unclear.
After a mean follow-up of 82 days, overall mortality was 2.17% in patients who received thrombolysis, compared with 3.89% in those who received anticoagulation. In addition, the risk of recurrent PE was significantly lower with thrombolytic therapy (1.17%) than with anticoagulation (3.04%).
However, the rate of major bleeding was 9.24% for thrombolytic therapy, compared with 3.42% for anticoagulation. And the rate of intracranial hemorrhage was 1.46% for thrombolysis, compared with 0.19% for anticoagulation, the investigators said.
The bleeding risk was especially high in patients aged 65 years and older. Attenuation of this risk in younger patients suggests that they may be considered stronger candidates for thrombolytic therapy, Dr. Chatterjee and his associates said.
Dr. Chatterjee reported no financial conflicts; his associates reported ties to AstraZeneca, Boston Scientific, Cardiostem, Cordis, EKOS Corporation, Embolitech, GenWay, Johnson & Johnson, Soteria, and Vascular Magnetics.
Thrombolytic therapy decreased all-cause mortality in patients with hemodynamically stable pulmonary embolism associated with right ventricular dysfunction – those at "intermediate risk," according to a meta-analysis published online June 17 in JAMA.
The investigators described their study of 16 randomized, controlled clinical trials involving 2,115 patients as "the first analysis of thrombolysis in PE that has sufficient statistical power to detect associations with a meaningful mortality reduction." If their findings are confirmed in future randomized clinical trials, "there may be a shift in the treatment of selected patients with intermediate-risk PE using thrombolytics."
However, "the optimism regarding this clinical advantage must be tempered by [our] finding of significantly increased risk of major bleeding and intracranial hemorrhage associated with thrombolytic therapy, particularly for patients older than 65 years," said Dr. Saurav Chatterjee of the division of cardiology, St. Luke’s-Roosevelt Hospital Center of the Mount Sinai Health System, New York, and his associates (JAMA 2014;311:2414-21).
The study population included 1,499 patients who had hemodynamically stable PE associated with right ventricular dysfunction, the largest subset of patients seen in clinical practice and the group for whom the risks and benefits of thrombolysis are the most unclear.
After a mean follow-up of 82 days, overall mortality was 2.17% in patients who received thrombolysis, compared with 3.89% in those who received anticoagulation. In addition, the risk of recurrent PE was significantly lower with thrombolytic therapy (1.17%) than with anticoagulation (3.04%).
However, the rate of major bleeding was 9.24% for thrombolytic therapy, compared with 3.42% for anticoagulation. And the rate of intracranial hemorrhage was 1.46% for thrombolysis, compared with 0.19% for anticoagulation, the investigators said.
The bleeding risk was especially high in patients aged 65 years and older. Attenuation of this risk in younger patients suggests that they may be considered stronger candidates for thrombolytic therapy, Dr. Chatterjee and his associates said.
Dr. Chatterjee reported no financial conflicts; his associates reported ties to AstraZeneca, Boston Scientific, Cardiostem, Cordis, EKOS Corporation, Embolitech, GenWay, Johnson & Johnson, Soteria, and Vascular Magnetics.
FROM JAMA
Key clinical point: Thrombolysis may be a therapeutic alternative to anticoagulation in some patients with stable, intermediate-risk pulmonary embolism.
Major finding: Mortality was 2.17% in PE patients who received thrombolysis, compared with 3.89% in those who received anticoagulation; the risk of recurrent PE also was significantly lower with thrombolytic therapy (1.17%) than with anticoagulation (3.04%).
Data source: A meta-analysis of 16 randomized, controlled trials involving 2,115 patients with PE, including 1,499 with intermediate-risk PE, who were followed for a mean of 82 days.
Disclosures: Dr. Chatterjee reported no financial conflicts; his associates reported ties to AstraZeneca, Boston Scientific, Cardiostem, Cordis, EKOS Corporation, Embolitech, GenWay, Johnson & Johnson, Soteria, and Vascular Magnetics.
